Netherlands· NL-ca30776743de
Portrazza, concentraat voor oplossing voor infusie
A necitumumab product containing necitumumab, registered in Netherlands by Eli Lilly Nederland BV. The same ATC class is registered in 5 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Necitumumab is registered in 5 of 19 countries.
Countries holding a registration under ATC L01FE03 (necitumumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 2 of them publish a price we can compare per daily dose
Necitumumab · ATC L01FE03
5 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Netherlands
- United Kingdom
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- NECITUMUMAB
- Manufacturer
- Eli Lilly Nederland BV
- Country
- Netherlands (NL)
- ATC code
- L01FE03
- ATC class
- Necitumumab
- Defined daily dose
- 76 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/15/1084
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for necitumumab.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Necitumumab · interactions on record
5 records
- 1 severe
- 3 moderate
- 1 minor
Most severe, free to view
- ThalidomideL04AX02severe
- IdelalisibL01EM01moderate
- IdelalisibL01XX47moderate
- PaliferminV03AF08moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Necitumumab in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b9b64c8d-6bec-4402-a7d7-0a7fdf2c0558 GET /v1/drugs/b9b64c8d-6bec-4402-a7d7-0a7fdf2c0558?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/portrazza-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Necitumumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp116755",
"excipients": [
"CITROENZUUR 0-WATER (E 330)",
"GLYCINE (E 640)",
"MANNITOL (D-) (E 421)",
"NATRIUMCHLORIDE",
"POLYSORBAAT 80 (E 433)",
"TRINATRIUMCITRAAT 2-WATER (E 331)",
"WATER VOOR INJECTIE"
],
"substances": [
"NECITUMUMAB"
],
"leaflet_url": null,
"authorised_at": "2016/02/15",
"procedure_number": "EMEA/H/C/003886",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/15/1084",
"additional_monitoring": "N"
}See everything about necitumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.